ATE211394T1 - Anti-cd40l immunotoxine zur behandlung von krankheiten - Google Patents
Anti-cd40l immunotoxine zur behandlung von krankheitenInfo
- Publication number
- ATE211394T1 ATE211394T1 AT98931129T AT98931129T ATE211394T1 AT E211394 T1 ATE211394 T1 AT E211394T1 AT 98931129 T AT98931129 T AT 98931129T AT 98931129 T AT98931129 T AT 98931129T AT E211394 T1 ATE211394 T1 AT E211394T1
- Authority
- AT
- Austria
- Prior art keywords
- cd40l
- immunotoxin
- molecule
- treatment
- diseases
- Prior art date
Links
- 239000002596 immunotoxin Substances 0.000 title abstract 4
- 231100000608 immunotoxin Toxicity 0.000 title abstract 4
- 229940051026 immunotoxin Drugs 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002637 immunotoxin Effects 0.000 abstract 3
- 108010029697 CD40 Ligand Proteins 0.000 abstract 2
- 102100032937 CD40 ligand Human genes 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 239000003053 toxin Substances 0.000 abstract 2
- 231100000765 toxin Toxicity 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101100059511 Homo sapiens CD40LG gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 108010061360 Type 1 Ribosome Inactivating Proteins Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Botany (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97201895 | 1997-06-20 | ||
| PCT/NL1998/000357 WO1998058678A1 (en) | 1997-06-20 | 1998-06-22 | Anti-cd40l immunotoxins for the treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE211394T1 true ATE211394T1 (de) | 2002-01-15 |
Family
ID=8228468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98931129T ATE211394T1 (de) | 1997-06-20 | 1998-06-22 | Anti-cd40l immunotoxine zur behandlung von krankheiten |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6645494B1 (de) |
| EP (1) | EP1005372B1 (de) |
| JP (1) | JP2002507967A (de) |
| AT (1) | ATE211394T1 (de) |
| AU (1) | AU8132998A (de) |
| CA (1) | CA2294223C (de) |
| DE (1) | DE69803392D1 (de) |
| WO (1) | WO1998058678A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6946129B1 (en) * | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| IL158532A0 (en) | 2001-05-02 | 2004-05-12 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
| CN1678634A (zh) * | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| EP1622646B1 (de) * | 2003-05-06 | 2012-08-08 | Purdue Research Foundation | Behandlung von Lupus mit den Makrophagen oder dem Folat-Rezeptor als Target |
| CA2560278C (en) * | 2004-03-19 | 2012-11-20 | Matthew Baker | Modified bouganin proteins, cytotoxins and methods and uses thereof |
| AU2005235718B2 (en) * | 2004-04-23 | 2011-09-22 | Bundesrepublik Deutschland Letztvertreten Durch Das Robert-Koch-Institut Vertreten Durch Seinen Prasidenten | Method for the treatment of T cell mediated conditions by depletion of icos-positive cells in vivo |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| JP5175723B2 (ja) | 2005-07-05 | 2013-04-03 | パーデュー・リサーチ・ファウンデーション | 単球介在性疾患を治療するための組成物の調製 |
| US8586595B2 (en) | 2007-02-07 | 2013-11-19 | Purdue Research Foundation | Positron emission tomography imaging method |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| CA2089229C (en) * | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
| AU6912294A (en) * | 1993-05-12 | 1994-12-12 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
| US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
-
1998
- 1998-06-22 AT AT98931129T patent/ATE211394T1/de active
- 1998-06-22 US US09/446,351 patent/US6645494B1/en not_active Expired - Fee Related
- 1998-06-22 WO PCT/NL1998/000357 patent/WO1998058678A1/en not_active Ceased
- 1998-06-22 CA CA2294223A patent/CA2294223C/en not_active Expired - Fee Related
- 1998-06-22 EP EP98931129A patent/EP1005372B1/de not_active Expired - Lifetime
- 1998-06-22 JP JP50421299A patent/JP2002507967A/ja active Pending
- 1998-06-22 AU AU81329/98A patent/AU8132998A/en not_active Abandoned
- 1998-06-22 DE DE69803392T patent/DE69803392D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU8132998A (en) | 1999-01-04 |
| EP1005372A1 (de) | 2000-06-07 |
| CA2294223C (en) | 2011-02-15 |
| CA2294223A1 (en) | 1998-12-30 |
| US6645494B1 (en) | 2003-11-11 |
| DE69803392D1 (de) | 2002-02-28 |
| WO1998058678A1 (en) | 1998-12-30 |
| EP1005372B1 (de) | 2002-01-02 |
| JP2002507967A (ja) | 2002-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2137935T3 (es) | Preparaciones farmaceuticas que contienen una anticitoquina. | |
| WO1998026747A3 (en) | Superantigen based methods and compositions for treatment of diseases | |
| ATE245030T1 (de) | Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen | |
| EP0765172A4 (de) | Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper | |
| NZ513699A (en) | Recombinant IL-18 antagonists useful in treatment of IL-18 mediated disorders | |
| DE69636760D1 (de) | Rekombinanter anti-cd4 antikörper zur menschlichen behandlung | |
| ATE242633T1 (de) | Dialkylfumarate zur behandlung von autoimmunerkrankungen | |
| TR199900666T2 (xx) | �nsan paratormonu ile ilgili peptidlere kar�� antikor. | |
| EP1137658A4 (de) | VERFAHREN ZUR MODULATION VON TUMOR NECROSIS FAKTOR -g(a)-INDUZIERTER EXPRESSION VON ZELLADHÄSIONSMOLEKÜLEN | |
| DE69435307D1 (de) | Bazillus Thuringiensis und dessen insektizide Proteine | |
| DE69703689D1 (de) | Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia | |
| NO971059D0 (no) | Modifiserte human-C3-proteiner | |
| DE69803392D1 (de) | Anti-cd40l immunotoxine zur behandlung von krankheiten | |
| DE69839566D1 (de) | Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten | |
| DK0812206T3 (da) | Fremgangsmåde til stimulering af en immunrespons | |
| HK21795A (en) | Cross-protective human monoclonal antibody compositions | |
| DE69535855D1 (de) | Calciumbindende rekombinante antikörper gegen protein c | |
| HUP9802961A2 (hu) | Kötési partner ciklinfüggő kinázok inhibitoraihoz és ezek alkalmazása inhibitorok kereséséhez, valamint egy betegség diagnózisához vagy terápiájához | |
| EA200400134A1 (ru) | Терапевтический агент | |
| WO1996040260A3 (en) | Immunotoxins specific for cd80 and cd86 expressing cells | |
| DE69817379D1 (de) | Pharmazeutische zubereitungen enthaltend ibuprofen und domperidon zur behandlung von migräne | |
| EA200001127A1 (ru) | Бактериальные феромоны и их использование | |
| KR910006478A (ko) | 인체 트립타제 유사 단백질 | |
| DE69813620D1 (de) | Verwendung von citrullin enthaltenden peptiden, die von filaggrin abstammen, zur behandlung von autoimmunkrankheiten | |
| UA36408A (uk) | Пристрій для проведення досліджень на лабораторних тваринах |